{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:59:51Z","timestamp":1789412391805,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010265","name":"Guizhou Medical University","doi-asserted-by":"publisher","award":["[2022]102"],"award-info":[{"award-number":["[2022]102"]}],"id":[{"id":"10.13039\/501100010265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22267003"],"award-info":[{"award-number":["22267003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023B1515020042"],"award-info":[{"award-number":["2023B1515020042"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.apsb.2025.09.010","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:48:56Z","timestamp":1757774936000},"page":"4166-4195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Computation-driven discovery of novel chromone derivatives for the treatment of triple-negative breast cancer via mTOR-targeted inhibition and triggering antitumor immunity"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8034-7551","authenticated-orcid":false,"given":"Ji-Quan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsheng","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangrong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weike","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-7749","authenticated-orcid":false,"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5215-2829","authenticated-orcid":false,"given":"Changyou","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.09.010_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.apsb.2025.09.010_bib2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.09.010_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer-expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2025.09.010_bib4","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1021\/acs.jmedchem.0c01180","article-title":"Small-molecule drug discovery in triple negative breast cancer: current situation and future directions","volume":"64","author":"Liao","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.010_bib5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.09.010_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.09.010_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115620","article-title":"The mTOR signalling in corneal diseases: a recent update","volume":"213","author":"Li","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2025.09.010_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2025.09.010_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","article-title":"PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.apsb.2025.09.010_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.apsb.2019.10.003","article-title":"Targeting autophagy-related protein kinases for potential therapeutic purpose","volume":"10","author":"Xiang","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.apsb.2025.09.010_bib11","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41467-023-36881-7","article-title":"mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.apsb.2025.09.010_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.09.010_bib13","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1172\/JCI86892","article-title":"The host STING pathway at the interface of cancer and immunity","volume":"126","author":"Corrales","year":"2016","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2025.09.010_bib14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2025.09.010_bib15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2025.09.010_bib16","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2025.09.010_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.tcb.2022.11.001","article-title":"Cellular functions of cGAS-STING signaling","volume":"33","author":"Chen","year":"2023","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.apsb.2025.09.010_bib18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature24050","article-title":"Cytoplasmic chromatin triggers inflammation in senescence and cancer","volume":"550","author":"Dou","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.09.010_bib19","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1158\/1078-0432.CCR-11-1142","article-title":"TLR2 Agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy","volume":"17","author":"Lu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.09.010_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","article-title":"Role of immunotherapy in triple-negative breast cancer","volume":"18","author":"Keenan","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.apsb.2025.09.010_bib21","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","article-title":"PI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges","volume":"24","author":"Khan","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2025.09.010_bib22","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-16-3055","volume":"23","author":"Jovanovic","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"R32\/1","key":"10.1016\/j.apsb.2025.09.010_bib23","article-title":"Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer","volume":"16","author":"Singh","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2025.09.010_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1090-7","article-title":"Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer","volume":"15","author":"Jang","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.apsb.2025.09.010_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.biopha.2017.05.051","article-title":"Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells","volume":"92","author":"Torki","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.09.010_bib26","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-19-3498","article-title":"Preclinical and dose-finding phase I trial results of combined treatment with a TORC1\/2 inhibitor (TAK-228) and aurora A kinase inhibitor (Alisertib) in solid tumors","volume":"26","author":"Davis","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.09.010_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112391","article-title":"Targeting mTOR for fighting diseases: a revisited review of mTOR inhibitors","volume":"199","author":"Xu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.010_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2025.09.010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103992","article-title":"Unleashing the power of generative AI in drug discovery","volume":"29","author":"Gangwal","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2025.09.010_bib30","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/acs.jcim.4c01966","article-title":"AI-driven drug discovery for rare diseases","volume":"65","author":"Gangwal","year":"2025","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2025.09.010_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/bib\/bbac408","article-title":"FP-GNN: a versatile deep learning architecture for enhanced molecular property prediction","volume":"23","author":"Cai","year":"2022","journal-title":"Briefings Bioinf"},{"key":"10.1016\/j.apsb.2025.09.010_bib32","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1021\/acs.jmedchem.4c00173","article-title":"Design, synthesis, formulation, and bioevaluation of trisubstituted triazines as highly selective mTOR inhibitors for the treatment of human breast cancer","volume":"67","author":"Sun","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.010_bib33","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1021\/acs.jmedchem.6b00235","article-title":"Design, synthesis, and biological evaluation of substituted pyrimidines as potential phosphatidylinositol 3-kinase (PI3K) inhibitors","volume":"59","author":"Zhang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.010_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114055","article-title":"Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer","volume":"229","author":"Wu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.010_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106781","article-title":"Virtual screening of novel mTOR inhibitors for the potential treatment of human colorectal cancer","volume":"140","author":"Zhang","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2025.09.010_bib36","doi-asserted-by":"crossref","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in the treatment of human diseases: current status, trends, and solutions","volume":"65","author":"Huang","year":"2022","journal-title":"J Med Chem"},{"issue":"59","key":"10.1016\/j.apsb.2025.09.010_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1021\/acs.jcim.8b00363","article-title":"Practical model selection for prospective virtual screening","volume":"28","author":"Liu","year":"2019","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2025.09.010_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115754","article-title":"Design, synthesis and bioevaluation of PI3K\u03b1-selective inhibitors as potential colorectal cancer drugs","volume":"260","author":"Zheng","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.010_bib39","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/cmdc.202100332","article-title":"Chemical and structural strategies to selectively target mTOR kinase","volume":"16","author":"Borsari","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2025.09.010_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2025.09.010_bib41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrc1075","article-title":"Tumor-cell invasion and migration: diversity and escape mechanisms","volume":"3","author":"Friedl","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2025.09.010_bib42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2025.09.010_bib43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2025.09.010_bib44","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00018-013-1555-2","article-title":"The nuclear \u03b3-H2AX apoptotic ring: implications for cancers and autoimmune diseases","volume":"71","author":"Solier","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2025.09.010_bib45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00253-019-10257-8","article-title":"Targeting PI3K\/AKT\/mTOR-mediated autophagy for tumor therapy","volume":"104","author":"Xu","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.010_bib46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.redox.2014.12.003","article-title":"Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy","volume":"4","author":"Poillet-Perez","year":"2015","journal-title":"Redox Biol"},{"key":"10.1016\/j.apsb.2025.09.010_bib47","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1038\/ncomms8014","article-title":"A REDD1\/TXNIP pro-oxidant complex regulates ATG4B activity to control stress-induced autophagy and sustain exercise capacity","volume":"6","author":"Qiao","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.010_bib48","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41392-022-01252-z","article-title":"Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2025.09.010_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/jm501026z","article-title":"Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring","volume":"58","author":"Andrs","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.09.010_bib50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1021\/acsbiomedchemau.3c00046","article-title":"Shape-based virtual screening of a billion-compound library identifies mycobacterial lipoamide dehydrogenase inhibitors","volume":"3","author":"Michino","year":"2023","journal-title":"ACS Bio & Med Chem Au"},{"key":"10.1016\/j.apsb.2025.09.010_bib51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00894-022-05096-w","article-title":"Computational study reveals substituted benzimidazole derivatives' binding selectivity to PI3K\u03b4 and PI3K\u03b3","volume":"28","author":"Zhang","year":"2022","journal-title":"J Mol Model"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:19:22Z","timestamp":1785975562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525006070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2211383525006070"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.09.010","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computation-driven discovery of novel chromone derivatives for the treatment of triple-negative breast cancer via mTOR-targeted inhibition and triggering antitumor immunity","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}